Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Common Equity (2021 - 2025)

Historic Common Equity for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $71.8 million.

  • Aligos Therapeutics' Common Equity rose 4339.07% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.8 million, marking a year-over-year increase of 4339.07%. This contributed to the annual value of -$29.0 million for FY2024, which is 13146.5% down from last year.
  • Latest data reveals that Aligos Therapeutics reported Common Equity of $71.8 million as of Q3 2025, which was up 4339.07% from $101.9 million recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Common Equity peaked at $217.0 million during Q3 2021, and registered a low of -$29.0 million during Q4 2024.
  • For the 5-year period, Aligos Therapeutics' Common Equity averaged around $106.4 million, with its median value being $101.9 million (2025).
  • In the last 5 years, Aligos Therapeutics' Common Equity crashed by 13146.5% in 2024 and then surged by 9473.71% in 2025.
  • Aligos Therapeutics' Common Equity (Quarter) stood at $184.7 million in 2021, then tumbled by 43.76% to $103.9 million in 2022, then decreased by 11.38% to $92.1 million in 2023, then plummeted by 131.47% to -$29.0 million in 2024, then soared by 347.93% to $71.8 million in 2025.
  • Its Common Equity was $71.8 million in Q3 2025, compared to $101.9 million in Q2 2025 and $116.4 million in Q1 2025.